Biomarkers.

Background: The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is one of the biggest health concerns of the century. Long COVID is one of the major sequelae from the infection and include persistent neurological manifestations. Brain images study suggest that Long COVID patients present distinct brain metabolic alterations.

Biomarkers.

Background: The COVID-19 pandemic is a public health crisis, and its lasting consequences are not yet fully understood. Epidemiological data suggest that low- and middle-income countries, such as Brazil, will bear a considerable burden of COVID-19-related comorbidities. Individuals who have survived COVID-19 often report persistent symptoms, including neurological manifestations such as brain fog.

Biomarkers.

Background: Current evidence indicates that COVID-19 infection can lead to neurological complications that persist beyond 12 weeks of infection (long-COVID), often associated with cognitive decline. However, the underlying mechanisms remain unclear. Our aim is to study the brain metabolism of patients with long-COVID and its association with cognitive performance.

Biomarkers.

Background: Screen failure due to amyloid negativity is yet a problem in clinical trials for anti-amyloid drugs. In this context, clinical characteristics of patients presenting with cognitive decline may decrease the screen failure ratio by increasing the odds of selecting individuals with brain amyloid pathology. Herein, we aimed at estimating amyloid and tau positivity in individuals using clinical variables in a machine learning model of prediction.

Biomarkers.

Background: Alzheimer's disease (AD) has been known for more than a century, but its complex pathophysiology remains unclear. Previous studies have been suggesting a potential role of neuroinflammation and cerebral vascular changes in AD progression. Part of the immune response relies on the role of Vascular Cell Adhesion Molecule (VCAM) in cell transit through the endothelium.